In the Claims

The following amendments are made with respect to the claims in the International application PCT/GB2004/004740.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (original). A dry powder composition comprising recombinant human alpha 1-antitrypsin (rAAT).

2 (original). The dry powder composition of claim 1, that has not been subjected to viral inactivation.

3 (currently amended). The dry powder composition of claim 1 ~~or claim 2~~, whose protein content is less than 10%~~, more preferably less than 5%, most preferably less than 1%~~ α1-antichymotrypsin.

4 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, whose protein content is less than 10%~~, more preferably less than 5%, most preferably less than 1%~~ albumin.

5 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, whose protein content is less than 10%~~, more preferably less than 5%, most preferably less than 1%~~ human protein.

6 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, whose protein content is more than 90% rAAT.

7 (original). The dry powder composition of claim 6, whose protein content is more than 95% rAAT.

8 (original). The dry powder composition of claim 6, whose protein content is more than 99% rAAT.

9 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, further comprising 1 to 2000 milliequivalents salt per 100 mg of rAAT~~, more preferably 50-500 milliequivalents, most preferably 100-200 milliequivalents~~.

10 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, that is free of sugar.

11 (currently amended) The dry powder composition of ~~any preceding~~ claim 1, that contains less than 1% water.

12 (original). The dry powder composition of claim 11, that contains less than 0.5% water.

13 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, that retains at least 80% of initial rAAT activity~~, preferably more than 90%,~~ upon storage [[at]] under conditions that are, or are equivalent to, 50°C for 3 months.

14 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, that retains at least 80% monomeric rAAT~~, preferably > 95% monomer,~~ upon storage under conditions that are, or are equivalent to, 50°C for 3 months.

15 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, further comprising a reducing agent~~, such as glutathione, cysteine, dithiothreitol or N-acetyl cysteine~~.

16 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, further comprising an antioxidant~~, such as ascorbic acid or L-methionine~~.

17 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, further comprising a buffer~~, such as histidine, phosphate or citrate~~.

18 (currently amended). The dry powder composition of claim 17, wherein the buffer is such that, on reconstitution of the composition in water, the reconstituted solution has a pH of from about 6 to 9~~, more preferably, 6.5 – 8, preferably from 6.8 – 7.0~~.

19 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, further comprising a chelating agent~~, such as EDTA or citrate~~.

20 (currently amended). The dry powder composition of ~~any preceding~~ claim 1, further comprising a surfactant~~ such as polyoxyethylene sorbitan oleate~~.

21 (currently amended). The dry powder composition of claim 1, that consists essentially only of rAAT and ~~the components defined in claims 9, 15, 16, 17 and 20~~ 1 to 2000 milliequivalents salt per 100 mg of rAAT, a reducing agent, an antioxidant, a buffer and a surfactant.